The average Chinese person now accounts for more carbon emissions annually than the average European
The latest Ferrari glitch may or may not be a flaw, depending on how often you plan to use your $234,000 sports car in kidnappings
NASA's decision to hire both Boeing and SpaceX to design and build new space shuttles illustrates a debate in government contracting as to how many suppliers is best
The photo agency is increasingly making its work available to customers without a licensing fee, with the plan to develop a business model at some point in the future
The popular premixed funds are supposed to get more conservative as retirement gets closer. What “conservative” means is open to interpretation
Airbus has reduced the width of a bathroom on the new A320s to restore space in the food-preparation area
Has anyone enjoyed being a CEO more than Oracle's sort-of outgoing Larry Ellison?
Business students at Wharton reveled in a ritual gathering of MBAs where people leave their personal brand at the door
Evan Thornley, Australian multimillionaire and co-founder of online advertising company LookSmart, has since apologized
Founder: Dr. Mark Pruzanski
VC Investment over the last four quarters: $25 million
Founded in 2002, the 25-employee biopharmaceutical company is in the process of developing therapeutic treatment of chronic fibrotic and metabolic diseases. Despite the downturn, the company raised significant funding this year. Sticking to a tight budget, Intercept expects to have enough cash resources to fund its operations until 2010.
Key to startup success: "Be persistent. Intercept was founded just before the last major downturn for biotech, which lasted through 2003 and venture capital completely dried up for new early-stage startups. [We] remained passionately dedicated to the company and persisted even though it took more than a year to secure financing."